Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Bonus Article Is Abbott's January Pullback a Good Time to Buy? Submitted by Thomas Hughes. Date Posted: 1/24/2026. 
In Brief - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 pullback makes the stock look attractively valued. The decline appears driven more by market angst than by fundamental weakness — a knee-jerk reaction that has pushed the shares back into a potential buy zone. 
Rich or poor, left or right, young or old, a dark cloud is hanging over the nation. Everyone senses something is coming. They just don't know what it is or when it will hit. This division isn't really about politics or left versus right. These cracks and unrest are symptoms of something far deeper. It's the real reason support for socialism is soaring, why nearly 70 percent believe the American Dream is dead, and why Americans from coast to coast are losing hope. It's all connected, and most people don't understand it. Click here to reveal the truth behind the nationwide unease. The zone in question aligns with market action from 2022 to 2024, when Abbott was recovering from its post-COVID-19 revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates The most notable criticism of Abbott's Q4 results and guidance is that some metrics missed market expectations. Still, revenue of $11.46 billion rose 4.5% year-over-year, margins improved, and adjusted earnings accelerated. Revenue growth lagged consensus by several hundred basis points, but margin strength helped offset that shortfall. Adjusted earnings per share (EPS) rose about 12%, coming in slightly above consensus. By segment, the report highlighted the resilience of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted — Nutrition fell nearly 9% — but those declines were offset by solid growth in Established Pharmaceuticals and Med Tech. Established Pharmaceuticals grew roughly 9%, powered by generics and emerging markets, while Med Tech expanded about 12.3% with broad-based strength across subsegments. Margins were a constructive element of the print. Although they were modestly below some analyst forecasts, a favorable product mix, strength in Med Tech, lower COVID-19 sales and operational improvements helped margins move in the right direction. Management expects earnings to grow another ~10% in 2026, outpacing revenue growth and supporting the company's capital-return plans. Capital returns are central to the investment case. Abbott is a Dividend King, having raised its payout for more than 50 consecutive years, and it should have capacity to continue that trend. After the pullback, the yield sits around 2.5%, and the company currently pays out less than half of consensus earnings, leaving room for share buybacks — an important offset to dilutive share-based compensation. Analysts Point to a Potential Rebound Some analysts noted the revenue miss, but there were no major rating or price-target changes reported the morning of the earnings release. The prevailing view is that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth. The consensus share price target reported by MarketBeat implies potential upside of roughly 30%, which could take the stock back toward prior highs; even downside targets imply some upside from current levels. Key catalysts include Abbott's expanding Med Tech portfolio, integration of AI across operations and products, margin expansion and strategic acquisitions. The proposed Exact Sciences deal is one example of how acquisitions could broaden revenue and profit streams and enhance the product pipeline. That said, the recent decline has been steep and could deepen. Institutional investors bought shares throughout 2025 and are likely to be buyers again now that prices are discounted. Early technical support appears in the $105–$110 range, although it has not been firmly confirmed. The risk is that ABT could trade down toward the lower end of the buy zone before rebounding, potentially testing the mid-$90s.
| 
